Cannabis Bioscience International Holdings, Inc. (CBIH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cannabis Bioscience International Holdings, Inc. (CBIH) with AI Score 49/100 (Weak). Cannabis Bioscience International Holdings, Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cannabis Bioscience International Holdings, Inc. (CBIH) Healthcare & Pipeline Overview
Cannabis Bioscience International Holdings, Inc. (CBIH) operates in the medical cannabis education and therapeutic services sector, offering educational systems and clinical services. With a small team and a focus on online education and specialized treatments, CBIH navigates the competitive landscape of specialty drug manufacturers.
Investment Thesis
Cannabis Bioscience International Holdings, Inc. presents a high-risk, high-reward investment profile within the volatile medical cannabis sector. With a market capitalization of $0.01 billion and a negative P/E ratio of -8.83, the company's financial performance indicates significant challenges. A gross margin of 28.5% is offset by a substantial negative profit margin of -465.3%, reflecting high operational costs relative to revenue. Growth catalysts include expanding its online educational platform and potential advancements in its therapeutic services. However, the company's small size, limited resources, and OTC market listing contribute to a higher risk profile. Investors should carefully consider the speculative nature of CBIH within the evolving cannabis industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -8.83 reflects current unprofitability, suggesting the company is investing heavily in growth or facing operational challenges.
- Gross margin of 28.5% shows the company's ability to generate revenue from its services, but needs improvement to achieve profitability.
- Negative profit margin of -465.3% highlights significant operational inefficiencies or high expenses relative to revenue.
- Beta of 1.94 indicates higher volatility compared to the market, reflecting the speculative nature of the medical cannabis industry.
Competitors & Peers
Strengths
- Specialized focus on medical cannabis education and therapeutic services.
- Online education platform provides global reach.
- Established fertility and sleep center in Houston.
- Early mover advantage in the medical cannabis education market.
Weaknesses
- Small size and limited resources.
- Negative profitability and high operational costs.
- OTC market listing increases risk and reduces liquidity.
- Dependence on the evolving medical cannabis industry.
Catalysts
- Ongoing: Expansion of online education platform through Pharmacology University.
- Ongoing: Development of new therapeutic services at the fertility and sleep center.
- Upcoming: Potential strategic partnerships with other companies in the medical cannabis industry.
- Upcoming: Geographic expansion into new markets, particularly in Latin America.
- Ongoing: Clinical trials and research to validate the efficacy of therapeutic treatments.
Risks
- Potential: Changing regulations and market dynamics in the medical cannabis industry.
- Ongoing: Competition from larger companies with greater resources.
- Potential: Negative publicity and reputational risks.
- Ongoing: Economic downturns and reduced consumer spending.
- Ongoing: Limited liquidity and high volatility due to OTC market listing.
Growth Opportunities
- Expansion of Online Education Platform: CBIH can leverage the growing demand for medical cannabis education by expanding its online platform, Pharmacology University. This includes developing new courses, certifications, and partnerships with healthcare professionals. The global e-learning market is projected to reach $325 billion by 2025, providing a significant opportunity for CBIH to increase its revenue and market share. Timeline: Ongoing.
- Development of Therapeutic Services: CBIH's fertility and sleep center in Houston offers specialized treatments for sleep disorders and related infertility. By investing in research and development, CBIH can expand its therapeutic offerings and attract more patients. The market for sleep disorder treatments is expected to reach $11.2 billion by 2027, presenting a substantial growth opportunity. Timeline: Ongoing.
- Strategic Partnerships and Franchising: CBIH can pursue strategic partnerships with other companies in the medical cannabis industry to expand its reach and service offerings. Franchising its Pharmacology University can also generate additional revenue and brand awareness. The franchising market is estimated at over $750 billion globally, offering a scalable growth model. Timeline: 12-24 months.
- Geographic Expansion: CBIH can expand its educational and therapeutic services to new geographic markets, particularly in Latin America, where the medical cannabis industry is growing rapidly. This includes establishing partnerships with local healthcare providers and adapting its offerings to meet local regulations and market needs. The Latin American cannabis market is projected to reach $8.5 billion by 2028. Timeline: 18-36 months.
- Clinical Trials and Research: CBIH can conduct clinical trials and research to validate the efficacy of its therapeutic treatments and develop new products. This can enhance its credibility and attract funding from investors and research institutions. The global clinical trials market is expected to reach $68.9 billion by 2028, providing opportunities for CBIH to participate in research and development. Timeline: Ongoing.
Opportunities
- Expansion of online education platform and course offerings.
- Development of new therapeutic services and treatments.
- Strategic partnerships and franchising opportunities.
- Geographic expansion into new markets, particularly in Latin America.
Threats
- Changing regulations and market dynamics in the medical cannabis industry.
- Competition from larger companies with greater resources.
- Potential for negative publicity and reputational risks.
- Economic downturns and reduced consumer spending.
Competitive Advantages
- Specialized Focus: CBIH's focus on medical cannabis education and therapeutic services provides a niche market position.
- Proprietary Content: Pharmacology University's curriculum and educational materials offer a unique value proposition.
- First-Mover Advantage: Early entry into the medical cannabis education market provides a competitive edge.
- Established Infrastructure: The fertility and sleep center in Houston provides a physical location for therapeutic services.
About CBIH
Founded in 2003 and headquartered in Houston, Texas, Cannabis Bioscience International Holdings, Inc., formerly known as China Infrastructure Construction Corp., has evolved to focus on the medical cannabis industry. The company provides educational systems centered on medical cannabis in the United States, Latin America, and globally through online platforms. CBIH also offers services in therapeutic areas such as clinical trials and treatments for sleep disorders, including infertility resulting from these disorders, through its fertility and sleep center located in Houston. The company's offerings extend to education, consulting, digital publishing, marketing, and franchising related to medical cannabis through its Pharmacology University. CBIH operates with a small team, emphasizing specialized services within the burgeoning medical cannabis market.
What They Do
- Provides educational systems focused on medical cannabis.
- Offers online education through Pharmacology University.
- Provides services in therapeutic areas, including clinical trials.
- Treats sleep disorders and related infertility.
- Offers consulting services related to medical cannabis.
- Engages in digital publishing and marketing related to medical cannabis.
- Explores franchising opportunities for its educational programs.
Business Model
- Generates revenue through online education programs and courses.
- Provides therapeutic services at its fertility and sleep center.
- Offers consulting and marketing services to businesses in the medical cannabis industry.
- Explores franchising opportunities to expand its educational reach.
Industry Context
Cannabis Bioscience International Holdings, Inc. operates within the rapidly evolving medical cannabis industry. This sector is characterized by increasing acceptance of cannabis for medical purposes, driving growth in related services such as education, clinical trials, and therapeutic treatments. The competitive landscape includes both established pharmaceutical companies and emerging cannabis-focused businesses. CBIH's focus on education and specialized treatments positions it within a niche segment, but it faces competition from larger players with greater resources and market reach. The industry is subject to changing regulations and market dynamics, requiring companies to adapt quickly to maintain competitiveness.
Key Customers
- Healthcare professionals seeking education and training in medical cannabis.
- Patients seeking treatment for sleep disorders and related infertility.
- Businesses in the medical cannabis industry seeking consulting and marketing services.
- Individuals interested in learning about medical cannabis through online courses.
Financials
Chart & Info
Cannabis Bioscience International Holdings, Inc. (CBIH) stock price: Price data unavailable
Latest News
No recent news available for CBIH.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBIH.
Price Targets
Wall Street price target analysis for CBIH.
MoonshotScore
What does this score mean?
The MoonshotScore rates CBIH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dante Picazo
CEO
Dante Picazo serves as the CEO of Cannabis Bioscience International Holdings, Inc. His background includes managing small teams and navigating the complexities of the emerging medical cannabis industry. With a focus on strategic development and operational efficiency, Picazo is responsible for guiding the company's growth and expansion in the competitive healthcare sector. His leadership is crucial in driving CBIH's initiatives in education, therapeutic services, and market positioning.
Track Record: Under Dante Picazo's leadership, CBIH has focused on expanding its online education platform and developing its therapeutic services. Key milestones include the establishment of the fertility and sleep center in Houston and the development of new online courses for Pharmacology University. His strategic decisions aim to capitalize on the growing demand for medical cannabis education and treatments, while navigating the challenges of the OTC market and limited resources.
CBIH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cannabis Bioscience International Holdings, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Unlike stocks listed on major exchanges like NYSE or NASDAQ, OTC Other stocks have less stringent listing requirements, resulting in increased volatility and uncertainty.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status makes it challenging to assess the company's financial health.
- Regulatory Uncertainty: OTC market stocks are subject to less regulatory oversight than exchange-listed stocks.
- Volatility: OTC stocks can experience significant price fluctuations due to limited trading activity.
- Potential for Fraud: The OTC market is more susceptible to fraud and manipulation than major exchanges.
- Verify the company's registration and legal standing.
- Research the company's management team and their track record.
- Attempt to locate and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 2003.
- Focus on medical cannabis education and therapeutic services.
- Presence of a physical location (fertility and sleep center in Houston).
- Operation of Pharmacology University as an online education platform.
CBIH Healthcare Stock FAQ
What does Cannabis Bioscience International Holdings, Inc. do?
Cannabis Bioscience International Holdings, Inc. operates in the medical cannabis sector, focusing on education and therapeutic services. The company provides educational systems through its Pharmacology University, offering online courses and training programs. Additionally, CBIH offers therapeutic services, including clinical trials and treatments for sleep disorders and related infertility, through its fertility and sleep center in Houston. The company aims to capitalize on the growing demand for medical cannabis education and specialized treatments, while navigating the challenges of the evolving industry.
What do analysts say about CBIH stock?
Given CBIH's micro-cap status and OTC listing, formal analyst coverage is unlikely. The company's financial metrics, including a negative P/E ratio and a negative profit margin, suggest significant challenges. Potential investors should focus on the company's growth initiatives, such as expanding its online education platform and developing its therapeutic services. However, the risks associated with OTC stocks and the evolving medical cannabis industry should be carefully considered. Independent research and due diligence are essential for evaluating CBIH's investment potential.
What are the main risks for CBIH?
Cannabis Bioscience International Holdings, Inc. faces several key risks, including regulatory uncertainty in the medical cannabis industry, competition from larger companies with greater resources, and potential negative publicity. The company's OTC market listing increases liquidity risk and volatility. Additionally, CBIH's financial performance, characterized by negative profitability and high operational costs, poses a significant challenge. Investors should carefully assess these risks and conduct thorough due diligence before considering an investment in CBIH.
What are the key factors to evaluate for CBIH?
Cannabis Bioscience International Holdings, Inc. (CBIH) currently holds an AI score of 49/100, indicating low score. Key strength: Specialized focus on medical cannabis education and therapeutic services.. Primary risk to monitor: Potential: Changing regulations and market dynamics in the medical cannabis industry.. This is not financial advice.
How frequently does CBIH data refresh on this page?
CBIH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBIH's recent stock price performance?
Recent price movement in Cannabis Bioscience International Holdings, Inc. (CBIH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on medical cannabis education and therapeutic services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBIH overvalued or undervalued right now?
Determining whether Cannabis Bioscience International Holdings, Inc. (CBIH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBIH?
Before investing in Cannabis Bioscience International Holdings, Inc. (CBIH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights in the future.